Zentalis Pharmaceuticals (ZNTL) Financials

$4.46 +0.10 (+2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$4.56 +0.10 (+2.24%)

As of 05:43 PM Eastern

Annual Income Statements for Zentalis Pharmaceuticals

This table shows Zentalis Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-46	-118	-159	-237	-292	-166	-137
Consolidated Net Income / (Loss)	-46	-119	-166	-237	-292	-166	-137
Net Income / (Loss) Continuing Operations	-46	-119	-166	-237	-292	-166	-137
Total Pre-Tax Income	-46	-118	-165	-221	-277	-166	-137
Total Operating Income	-47	-119	-217	-227	-300	-191	-153
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	67	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	67	0.00
Operating Revenue	-	-	-	0.00	0.00	67	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	47	119	217	227	300	259	153
Selling, General & Admin Expense	8.46	34	41	55	64	87	38
Research & Development Expense	38	85	176	173	235	168	107
Impairment Charge	-	-	-	0.00	0.00	3.74	0.00
Restructuring Charge	-	-	-	-	0.00	0.00	7.80
Total Other Income / (Expense), net	0.48	0.68	52	5.99	23	26	16
Other Income / (Expense), net	0.48	0.68	0.40	5.99	23	26	16
Income Tax Expense	0.02	0.44	-0.30	-0.47	-0.60	0.18	0.44
Other Gains / (Losses), net	-	0.00	-1.83	-16	-16	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.72	-0.71	-7.37	-0.31	-0.11	-0.03	0.00
Basic Earnings per Share	($8.16)	($4.19)	($3.72)	($4.48)	($4.47)	($2.33)	($1.91)
Weighted Average Basic Shares Outstanding	5.60M	28.11M	42.69M	52.86M	65.41M	71.08M	71.87M
Diluted Earnings per Share	($16.32)	($4.19)	($3.72)	($4.48)	($4.47)	($2.33)	($1.91)
Weighted Average Diluted Shares Outstanding	5.60M	28.11M	42.69M	52.86M	65.41M	71.08M	71.87M
Weighted Average Basic & Diluted Shares Outstanding	5.60M	28.11M	45.56M	59.42M	70.96M	71.81M	70.93M

This table shows Zentalis Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-56	-61	10	-88	-40	-47	-48	-27	-27	-35	-35
Consolidated Net Income / (Loss)	-56	-61	10	-88	-40	-47	-48	-27	-27	-35	-35
Net Income / (Loss) Continuing Operations	-56	-61	10	-88	-40	-47	-48	-27	-27	-35	-35
Total Pre-Tax Income	-56	-61	10	-88	-40	-48	-48	-27	-27	-35	-35
Total Operating Income	-63	-68	-25	-65	-51	-50	-46	-36	-34	-37	-38
Total Gross Profit	0.00	-	41	0.00	0.00	27	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	41	0.00	0.00	27	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	63	68	65	65	51	77	46	36	34	37	38
Selling, General & Admin Expense	16	16	16	17	15	40	11	8.45	11	7.91	9.14
Research & Development Expense	47	52	50	48	37	33	27	28	23	29	29
Restructuring Charge	-	-	0.00	0.00	0.00	-	7.80	0.00	0.00	-	0.00
Total Other Income / (Expense), net	7.21	6.85	35	-23	11	2.17	-2.66	9.18	7.04	2.62	2.62
Other Income / (Expense), net	7.21	6.85	35	-23	11	2.17	-	9.18	7.04	2.62	2.62
Income Tax Expense	0.03	-0.14	0.14	0.27	-0.03	-0.21	0.00	0.00	0.00	0.44	0.12
Basic Earnings per Share	($0.79)	($0.76)	$0.14	($1.24)	($0.56)	($0.67)	($0.67)	($0.37)	($0.37)	($0.50)	($0.50)
Weighted Average Basic Shares Outstanding	70.61M	65.41M	70.90M	71.04M	71.11M	71.08M	71.68M	71.99M	72.14M	71.87M	70.26M
Diluted Earnings per Share	($0.79)	($0.76)	$0.14	($1.24)	($0.56)	($0.67)	($0.67)	($0.37)	($0.37)	($0.50)	($0.50)
Weighted Average Diluted Shares Outstanding	70.61M	65.41M	71.19M	71.04M	71.11M	71.08M	71.68M	71.99M	72.14M	71.87M	70.26M
Weighted Average Basic & Diluted Shares Outstanding	70.77M	70.96M	71.01M	71.11M	71.27M	71.81M	71.95M	72.14M	72.25M	70.93M	71.19M

This table details how cash moves in and out of Zentalis Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	42	-11	6.31	-17	-15	5.81	2.09
Net Cash From Operating Activities	-39	-87	-154	-164	-208	-171	-125
Net Cash From Continuing Operating Activities	-39	-87	-154	-164	-208	-171	-125
Net Income / (Loss) Continuing Operations	-46	-119	-166	-237	-292	-166	-137
Consolidated Net Income / (Loss)	-46	-119	-166	-237	-292	-166	-137
Depreciation Expense	0.11	0.16	0.54	1.43	1.39	1.29	0.74
Amortization Expense	0.00	0.56	0.91	-3.73	-13	-8.00	-2.76
Non-Cash Adjustments To Reconcile Net Income	0.62	23	-6.01	63	91	18	23
Changes in Operating Assets and Liabilities, net	6.51	7.86	17	12	5.01	-17	-9.12
Net Cash From Investing Activities	-0.35	-285	-18	-114	-44	177	132
Net Cash From Continuing Investing Activities	-0.35	-285	-18	-114	-44	177	132
Purchase of Property, Plant & Equipment	-0.35	-0.76	-6.11	-2.55	-0.58	-0.22	0.00
Purchase of Investments	0.00	-401	-364	-533	-549	-128	-139
Sale of Property, Plant & Equipment	-	-	-	0.00	0.00	0.07	0.70
Sale and/or Maturity of Investments	0.00	117	366	422	505	305	270
Net Cash From Financing Activities	82	360	179	261	237	0.11	-4.28
Net Cash From Continuing Financing Activities	82	360	179	261	237	0.11	-4.28
Repurchase of Common Equity	-	-	-	-	0.00	0.00	-9.98
Issuance of Common Equity	0.00	346	180	261	237	0.35	5.69
Other Financing Activities, net	-	0.00	-1.15	0.00	0.00	-0.24	0.00
Cash Income Taxes Paid	0.02	0.02	0.02	0.01	0.14	0.36	0.09

This table details how cash moves in and out of Zentalis Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-156	-83	9.58	-0.64	4.29	-7.42	8.03	-4.33	1.47	-3.08	-4.07
Net Cash From Operating Activities	-39	-41	-52	-35	-44	-40	-33	-35	-27	-31	-33
Net Cash From Continuing Operating Activities	-39	-41	-52	-35	-44	-40	-33	-35	-27	-31	-33
Net Income / (Loss) Continuing Operations	-56	-61	10	-88	-40	-47	-48	-27	-27	-35	-35
Consolidated Net Income / (Loss)	-56	-61	10	-88	-40	-47	-48	-27	-27	-35	-35
Depreciation Expense	0.35	0.34	0.32	0.33	0.32	0.32	0.26	0.16	0.16	0.16	0.15
Amortization Expense	-2.12	-4.56	-2.76	-2.20	-1.65	-1.40	-1.03	-0.78	-0.52	-0.43	-0.22
Non-Cash Adjustments To Reconcile Net Income	14	14	-44	42	4.70	16	15	1.12	1.26	5.93	3.20
Changes in Operating Assets and Liabilities, net	4.78	10	-16	13	-7.26	-7.08	1.75	-8.33	-1.17	-1.38	-0.73
Net Cash From Investing Activities	-117	-42	62	34	48	32	40	30	28	32	30
Net Cash From Continuing Investing Activities	-117	-42	62	34	48	32	40	30	28	32	30
Purchase of Property, Plant & Equipment	-0.09	-0.17	-0.04	-0.18	-	-	0.00	-	-	-	-0.03
Purchase of Investments	-264	-96	-10	-19	-59	-39	-20	-40	-50	-30	-30
Sale of Property, Plant & Equipment	-	-	0.00	0.07	-	-	0.01	0.56	-	0.13	0.00
Sale and/or Maturity of Investments	147	54	72	54	107	72	60	70	78	63	60
Net Cash From Financing Activities	0.31	-	0.01	0.01	0.09	-	0.19	-	0.12	-4.59	-1.12
Net Cash From Continuing Financing Activities	0.31	-	0.01	0.01	0.09	-	0.19	-	0.12	-4.59	-1.12
Issuance of Common Equity	0.31	-	0.25	0.01	0.09	-	0.19	-	0.12	5.39	0.33
Other Financing Activities, net	-	-	-0.24	-	-	-	0.00	-	-	-	-1.45

This table presents Zentalis Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	87	366	455	539	552	430	289
Total Current Assets	69	345	351	452	497	386	253
Cash & Equivalents	67	55	60	43	28	34	36
Short-Term Investments	0.00	284	280	394	455	337	210
Prepaid Expenses	1.51	6.18	11	15	14	9.98	7.30
Plant, Property, & Equipment, net	0.50	1.10	8.15	7.71	5.82	4.70	2.77
Total Noncurrent Assets	18	19	96	80	49	40	33
Other Noncurrent Operating Assets	5.55	6.82	54	55	45	40	33
Total Liabilities & Shareholders' Equity	87	366	455	539	552	430	289
Total Liabilities	19	32	90	105	114	93	73
Total Current Liabilities	15	29	44	57	69	53	37
Accounts Payable	4.29	8.66	12	11	15	7.44	7.21
Accrued Expenses	11	20	32	45	54	45	29
Total Noncurrent Liabilities	4.16	3.58	46	49	45	40	36
Other Noncurrent Operating Liabilities	1.70	1.10	44	48	45	40	36
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-73	333	364	434	437	337	216
Total Preferred & Common Equity	-80	309	364	434	437	337	216
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-80	309	364	434	437	337	216
Common Stock	2.89	509	724	1,032	1,324	1,391	1,407
Retained Earnings	-83	-201	-360	-596	-889	-1,054	-1,191
Accumulated Other Comprehensive Income / (Loss)	0.00	0.04	-0.13	-1.35	2.19	0.56	0.20

This table presents Zentalis Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	586	557	492	451	384	352	327	253
Total Current Assets	528	504	440	400	343	312	288	218
Cash & Equivalents	111	38	37	41	42	38	39	32
Short-Term Investments	406	451	389	350	291	266	242	180
Prepaid Expenses	12	15	13	9.02	10	8.17	7.61	6.34
Plant, Property, & Equipment, net	6.39	5.68	5.34	5.02	3.25	3.09	2.93	2.65
Total Noncurrent Assets	51	48	47	45	38	37	36	32
Other Noncurrent Operating Assets	47	44	43	42	38	37	36	32
Total Liabilities & Shareholders' Equity	586	557	492	451	384	352	327	253
Total Liabilities	104	99	109	96	89	77	74	70
Total Current Liabilities	59	55	67	55	49	39	37	35
Accounts Payable	14	11	20	8.20	7.77	3.72	7.03	7.38
Accrued Expenses	45	44	46	47	42	35	30	28
Total Noncurrent Liabilities	45	44	42	41	39	38	37	35
Other Noncurrent Operating Liabilities	45	44	42	41	39	38	37	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	482	459	383	354	295	274	253	183
Total Preferred & Common Equity	482	459	383	354	295	274	253	183
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	482	459	383	354	295	274	253	183
Common Stock	1,310	1,336	1,349	1,360	1,398	1,404	1,409	1,410
Retained Earnings	-828	-878	-967	-1,007	-1,103	-1,130	-1,156	-1,227
Accumulated Other Comprehensive Income / (Loss)	-0.36	0.77	0.14	1.59	0.36	0.06	0.19	-0.05

This table displays calculated financial ratios and metrics derived from Zentalis Pharmaceuticals' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	40,613,857.00	45,305,544.00	57,069,491.00	70,765,771.00	-	72,250,779.00
DEI Adjusted Shares Outstanding	0.00	40,613,857.00	45,305,544.00	57,069,491.00	70,765,771.00	-	72,250,779.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-2.90	-3.50	-4.15	-4.13	-	-1.90
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%
EBITDA Growth	0.00%	-153.80%	-82.89%	-4.15%	-29.10%	40.27%	19.58%
EBIT Growth	0.00%	-154.74%	-83.01%	-2.39%	-25.12%	40.16%	17.55%
NOPAT Growth	0.00%	-153.57%	-82.29%	-4.96%	-31.78%	36.16%	20.08%
Net Income Growth	0.00%	-155.61%	-40.11%	-42.76%	-23.28%	43.26%	17.37%
EPS Growth	0.00%	74.33%	11.22%	-20.43%	0.22%	47.87%	18.03%
Operating Cash Flow Growth	0.00%	-121.81%	-77.48%	-6.27%	-26.91%	17.79%	26.70%
Free Cash Flow Firm Growth	0.00%	0.00%	-86.82%	-2.87%	-27.77%	22.91%	23.57%
Invested Capital Growth	0.00%	-536.43%	-156.30%	-86.87%	-85.37%	25.54%	12.42%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	66.24%	-100.00%
EBITDA Q/Q Growth	0.00%	-26.15%	-3.62%	-0.04%	1.48%	8.75%	9.00%
EBIT Q/Q Growth	0.00%	-26.39%	-3.62%	1.08%	2.28%	7.48%	8.63%
NOPAT Q/Q Growth	0.00%	-27.12%	-3.81%	-1.59%	-5.71%	8.64%	7.54%
Net Income Q/Q Growth	0.00%	-27.83%	-6.23%	-2.11%	-2.08%	7.51%	8.21%
EPS Q/Q Growth	0.00%	76.99%	-730.51%	3.86%	2.40%	3.72%	8.17%
Operating Cash Flow Q/Q Growth	0.00%	-19.50%	-6.69%	-0.19%	-1.60%	0.52%	6.54%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-6.14%	0.18%	-2.20%	-0.80%	10.91%
Invested Capital Q/Q Growth	0.00%	-219.90%	-6.30%	-16.82%	-31.05%	8.19%	-6.71%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-255.70%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-283.57%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-245.74%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-246.00%	0.00%
Tax Burden Percent	100.03%	100.38%	100.93%	107.15%	105.57%	100.11%	100.32%
Interest Burden Percent	100.00%	100.00%	76.14%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-67.78%	-59.01%	-47.60%	-59.39%	-67.09%	-42.83%	-49.53%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-33.74%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-33.78%	0.00%
Return on Common Equity (ROCE)	79.36%	-33.55%	-45.87%	-59.33%	-67.06%	-42.82%	-49.53%
Return on Equity Simple (ROE_SIMPLE)	57.90%	-38.42%	-45.64%	-54.66%	0.00%	-49.19%	0.00%
Net Operating Profit after Tax (NOPAT)	-33	-83	-152	-159	-210	-134	-107
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-198.50%	0.00%
Net Nonoperating Expense Percent (NNEP)	-20.20%	-17.45%	-4.05%	-18.66%	-17.56%	-7.50%	-9.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-36.66%	-47.93%	-39.69%	-49.47%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	129.20%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	248.82%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	383.57%	0.00%
Earnings before Interest and Taxes (EBIT)	-46	-118	-216	-221	-277	-166	-137
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-46	-117	-215	-224	-289	-172	-139
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	6.84	10.46	2.65	2.45	0.64	0.45
Price to Tangible Book Value (P/TBV)	0.00	7.13	10.57	2.67	2.47	0.64	0.45
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	3.20	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	209.81	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.98	-1.01	-1.03	-1.05	-1.08	-1.10	-1.11
Leverage Ratio	1.28	1.13	1.18	1.24	1.25	1.27	1.30
Compound Leverage Factor	1.28	1.13	0.89	1.24	1.25	1.27	1.30
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	217.08%	7.44%	0.14%	0.05%	0.02%	0.00%	0.00%
Common Equity to Total Capital	-117.08%	92.56%	99.86%	99.95%	99.98%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.87	38.54	23.52	4.53	2.65	-2.22	-5.63
Noncontrolling Interest Sharing Ratio	217.08%	43.14%	3.63%	0.09%	0.04%	0.01%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	4.62	12.07	7.98	7.98	7.16	7.32	6.93
Quick Ratio	4.52	11.85	7.73	7.72	6.96	7.13	6.73
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-77	-144	-148	-189	-145	-111
Operating Cash Flow to CapEx	-11,120.17%	-11,454.49%	-2,523.22%	-6,426.65%	-35,647.00%	-109,525.64%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.14	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	12.82	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	1.18	-5.13	-13	-25	-46	-34	-30
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	-1.70	0.00
Increase / (Decrease) in Invested Capital	0.00	-6.30	-8.02	-11	-21	12	4.21
Enterprise Value (EV)	247	1,796	3,431	691	589	-155	-148
Market Capitalization	165	2,109	3,808	1,149	1,072	216	98
Book Value per Share	($14.31)	$7.60	$8.03	$7.60	$6.18	$4.73	$2.99
Tangible Book Value per Share	($16.55)	$7.29	$7.95	$7.54	$6.13	$4.73	$2.99
Total Capital	68	333	364	434	437	337	216
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-67	-339	-378	-459	-483	-371	-246
Capital Expenditures (CapEx)	0.35	0.76	6.11	2.55	0.58	0.16	-0.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-22	-33	-42	-56	-38	-29
Debt-free Net Working Capital (DFNWC)	54	317	307	395	427	333	217
Net Working Capital (NWC)	54	317	307	395	427	333	217
Net Nonoperating Expense (NNE)	14	35	15	78	83	32	30
Net Nonoperating Obligations (NNO)	-67	-339	-378	-459	-483	-371	-246
Total Depreciation and Amortization (D&A)	0.11	0.72	1.45	-2.30	-12	-6.71	-2.02
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	-55.98%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	494.39%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	494.39%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($4.48)	($4.47)	($2.33)	($1.91)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	52.86M	65.41M	71.08M	71.87M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($4.48)	($4.47)	($2.33)	($1.91)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	52.86M	65.41M	71.08M	71.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	59.42M	70.96M	71.81M	70.93M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-83	-152	-159	-210	-131	-102
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-194.62%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-245.74%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7.28%

This table displays calculated financial ratios and metrics derived from Zentalis Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	70,609,407.00	70,765,771.00	70,765,771.00	71,013,233.00	71,107,967.00	-	71,811,508.00	71,951,934.00	72,135,453.00	72,250,779.00	70,931,016.00
DEI Adjusted Shares Outstanding	70,609,407.00	70,765,771.00	70,765,771.00	71,013,233.00	71,107,967.00	-	71,811,508.00	71,951,934.00	72,135,453.00	72,250,779.00	70,931,016.00
DEI Earnings Per Adjusted Shares Outstanding	-0.79	-0.86	0.14	-1.24	-0.56	-	-0.67	-0.37	-0.37	-0.49	-0.50
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-7.71%	-21.20%	112.15%	12.18%	27.53%	25.32%	-699.19%	69.41%	34.84%	28.12%	23.90%
EBIT Growth	-6.16%	-18.01%	116.74%	11.52%	27.61%	21.94%	-548.03%	69.47%	33.58%	27.06%	22.78%
NOPAT Growth	-15.73%	-31.24%	46.30%	37.31%	17.99%	26.61%	-30.79%	44.65%	34.41%	24.99%	17.03%
Net Income Growth	-1.91%	-10.83%	115.87%	21.58%	27.70%	22.10%	-580.87%	69.56%	33.54%	25.82%	26.78%
EPS Growth	17.71%	12.64%	113.08%	32.97%	29.11%	11.84%	-578.57%	70.16%	33.93%	25.37%	25.37%
Operating Cash Flow Growth	-16.46%	-8.76%	-5.46%	55.67%	-13.91%	2.21%	37.21%	1.23%	38.78%	22.07%	-0.98%
Free Cash Flow Firm Growth	-3.11%	-7.12%	32.10%	43.58%	-12.04%	-75.05%	-25.63%	-27.31%	3.28%	34.69%	-37.54%
Invested Capital Growth	-65.25%	-85.37%	-17.30%	-47.47%	-6.28%	25.54%	-22.70%	33.94%	24.64%	12.42%	21.56%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	44.03%	-13.99%	111.86%	-1,260.79%	53.82%	-17.46%	4.84%	43.95%	1.63%	-29.58%	-0.73%
EBIT Q/Q Growth	44.19%	-10.03%	116.67%	-964.29%	54.34%	-18.64%	4.31%	44.34%	0.68%	-30.28%	-1.32%
NOPAT Q/Q Growth	39.65%	-8.30%	48.64%	-86.77%	21.05%	3.08%	8.48%	20.97%	6.45%	-10.85%	-1.24%
Net Income Q/Q Growth	50.66%	-9.72%	116.48%	-979.25%	54.51%	-18.21%	-1.70%	44.34%	0.68%	-31.94%	-0.39%
EPS Q/Q Growth	57.30%	3.80%	118.42%	-985.71%	54.84%	-19.64%	0.00%	44.78%	0.00%	-35.14%	0.00%
Operating Cash Flow Q/Q Growth	51.23%	-5.00%	-28.02%	32.39%	-25.35%	9.86%	17.80%	-6.35%	22.31%	-14.75%	-6.52%
Free Cash Flow Firm Q/Q Growth	45.94%	11.95%	24.89%	-57.82%	-7.36%	-37.56%	46.10%	-59.93%	18.44%	7.12%	-13.52%
Invested Capital Q/Q Growth	-16.95%	-31.05%	33.64%	-44.98%	15.71%	8.19%	-9.36%	21.94%	3.85%	-6.71%	2.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	19.09%	0.00%	0.00%	-181.49%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	-61.06%	0.00%	0.00%	-185.55%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	25.11%	0.00%	0.00%	-177.47%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	24.75%	0.00%	0.00%	-176.71%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.06%	99.78%	98.60%	100.30%	99.93%	99.57%	100.00%	100.00%	100.00%	101.27%	100.34%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	105.82%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	1.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-62.89%	-67.09%	-51.87%	-42.99%	-42.89%	-42.83%	-59.45%	-49.55%	-49.18%	-49.53%	-51.93%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	1.95%	0.00%	0.00%	-24.37%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	1.92%	0.00%	0.00%	-24.26%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-62.87%	-67.06%	-51.86%	-42.98%	-42.88%	-42.82%	-59.45%	-49.55%	-49.18%	-49.53%	-51.93%
Return on Equity Simple (ROE_SIMPLE)	-59.44%	0.00%	-47.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-44	-48	-24	-46	-36	-35	-32	-25	-24	-26	-26
NOPAT Margin	0.00%	0.00%	-60.20%	0.00%	0.00%	-129.89%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.41%	-2.85%	7.65%	-8.71%	-0.92%	-2.95%	-3.98%	-0.45%	-0.92%	-2.93%	-3.25%
Return On Investment Capital (ROIC_SIMPLE)	-	-10.87%	-5.32%	-11.92%	-10.16%	-10.35%	-10.81%	-9.20%	-9.34%	-12.11%	-14.51%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	38.81%	0.00%	0.00%	148.91%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	122.25%	0.00%	0.00%	122.74%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	161.06%	0.00%	0.00%	285.55%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-56	-61	10	-88	-40	-48	-46	-27	-27	-35	-35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-57	-65	7.74	-90	-42	-49	-46	-27	-27	-35	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.94	2.45	2.43	0.76	0.74	0.64	0.39	0.30	0.43	0.45	0.91
Price to Tangible Book Value (P/TBV)	2.96	2.47	2.45	0.77	0.75	0.64	0.39	0.30	0.43	0.45	0.91
Price to Revenue (P/Rev)	0.00	0.00	27.50	7.16	6.45	3.20	4.25	3.11	4.05	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	15.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.06	-1.08	-1.07	-1.08	-1.09	-1.10	-1.09	-1.11	-1.11	-1.11	-1.14
Leverage Ratio	1.22	1.25	1.24	1.23	1.24	1.27	1.25	1.28	1.28	1.30	1.33
Compound Leverage Factor	1.22	1.25	1.24	1.23	1.24	1.27	1.32	1.28	1.28	1.30	1.33
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.03%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.97%	99.98%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.86	3.94	5.67	-0.75	-0.78	-1.32	-2.65	-3.09	-3.33	-4.47	-4.96
Noncontrolling Interest Sharing Ratio	0.04%	0.04%	0.02%	0.02%	0.02%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.97	7.16	9.19	6.59	7.29	7.32	6.94	7.99	7.76	6.93	6.19
Quick Ratio	8.77	6.96	8.92	6.39	7.13	7.13	6.73	7.78	7.55	6.73	6.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-30	-27	-20	-32	-34	-47	-25	-40	-33	-30	-34
Operating Cash Flow to CapEx	-42,489.01%	-23,467.63%	-129,935.00%	-30,292.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-96,929.41%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.08	0.07	0.08	0.14	0.06	0.06	0.07	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	6.46	6.77	7.11	12.82	6.02	6.38	6.76	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-35	-46	-30	-44	-37	-34	-37	-29	-28	-30	-29
Invested Capital Turnover	0.00	0.00	-1.45	-1.10	-1.13	-1.70	-0.80	-0.74	-0.83	0.00	0.00
Increase / (Decrease) in Invested Capital	-14	-21	-4.46	-14	-2.18	12	-6.86	15	9.10	4.21	7.99
Enterprise Value (EV)	900	589	626	-136	-130	-155	-218	-220	-172	-148	-46
Market Capitalization	1,416	1,072	1,115	290	262	216	114	83	109	98	166
Book Value per Share	$6.82	$6.18	$6.47	$5.39	$4.98	$4.73	$4.11	$3.82	$3.51	$2.99	$2.58
Tangible Book Value per Share	$6.77	$6.13	$6.42	$5.33	$4.93	$4.73	$4.11	$3.82	$3.51	$2.99	$2.58
Total Capital	482	437	459	383	354	337	295	274	253	216	183
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-517	-483	-489	-426	-391	-371	-332	-303	-281	-246	-212
Capital Expenditures (CapEx)	0.09	0.17	0.04	0.12	0.00	0.00	-0.01	-0.56	0.00	-0.13	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-47	-56	-40	-53	-46	-38	-39	-31	-30	-29	-29
Debt-free Net Working Capital (DFNWC)	469	427	449	373	345	333	293	273	251	217	183
Net Working Capital (NWC)	469	427	449	373	345	333	293	273	251	217	183
Net Nonoperating Expense (NNE)	12	13	-34	43	4.16	13	16	1.63	3.08	9.04	8.85
Net Nonoperating Obligations (NNO)	-517	-483	-489	-426	-391	-371	-332	-303	-281	-246	-212
Total Depreciation and Amortization (D&A)	-1.77	-4.22	-2.44	-1.87	-1.32	-1.08	-0.77	-0.62	-0.36	-0.27	-0.07
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-98.56%	-131.81%	-113.06%	-55.98%	-145.17%	-114.86%	-110.04%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	1,107.02%	919.44%	851.56%	494.39%	1,092.32%	1,014.61%	934.80%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	1,107.02%	919.44%	851.56%	494.39%	1,092.32%	1,014.61%	934.80%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.79)	($0.76)	$0.14	($1.24)	($0.56)	($0.67)	($0.67)	($0.37)	($0.37)	($0.50)	($0.50)
Adjusted Weighted Average Basic Shares Outstanding	70.61M	65.41M	70.90M	71.04M	71.11M	71.08M	71.68M	71.99M	72.14M	71.87M	70.26M
Adjusted Diluted Earnings per Share	($0.79)	($0.76)	$0.14	($1.24)	($0.56)	($0.67)	($0.67)	($0.37)	($0.37)	($0.50)	($0.50)
Adjusted Weighted Average Diluted Shares Outstanding	70.61M	65.41M	71.19M	71.04M	71.11M	71.08M	71.68M	71.99M	72.14M	71.87M	70.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	70.77M	70.96M	71.01M	71.11M	71.27M	71.81M	71.95M	72.14M	72.25M	70.93M	71.19M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-48	-24	-46	-36	-35	-26	-25	-24	-26	-26
Normalized NOPAT Margin	0.00%	0.00%	-60.20%	0.00%	0.00%	-129.89%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	25.11%	0.00%	0.00%	-177.47%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7.28%	0.00%

Financials Breakdown Chart

Zentalis Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zentalis Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Zentalis Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$137.06 million in 2025, rising from -$46.38 million in 2019. The previous period was -$165.87 million in 2024. View Zentalis Pharmaceuticals' forecast to see where analysts expect Zentalis Pharmaceuticals to go next.

Zentalis Pharmaceuticals' total operating income in 2025 was -$152.81 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $152.81 million

Over the last 6 years, Zentalis Pharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Zentalis Pharmaceuticals' total liabilities were at $72.76 million at the end of 2025, a 21.9% decrease from 2024, and a 281.8% increase since 2019.

In the past 6 years, Zentalis Pharmaceuticals' cash and equivalents has ranged from $28.04 million in 2023 to $67.25 million in 2019, and is currently $36.00 million as of their latest financial filing in 2025.

Over the last 6 years, Zentalis Pharmaceuticals' book value per share changed from -14.31 in 2019 to 2.99 in 2025, a change of -120.9%.

Related Companies

Financial statements for NASDAQ:ZNTL last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Financials

Financials Breakdown Chart

Zentalis Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Financials

Annual Income Statements for Zentalis Pharmaceuticals

Quarterly Income Statements for Zentalis Pharmaceuticals

Annual Cash Flow Statements for Zentalis Pharmaceuticals

Quarterly Cash Flow Statements for Zentalis Pharmaceuticals

Annual Balance Sheets for Zentalis Pharmaceuticals

Quarterly Balance Sheets for Zentalis Pharmaceuticals

Annual Metrics And Ratios for Zentalis Pharmaceuticals

Quarterly Metrics And Ratios for Zentalis Pharmaceuticals

Financials Breakdown Chart

Zentalis Pharmaceuticals Financials - Frequently Asked Questions

When does Zentalis Pharmaceuticals' fiscal year end?

How has Zentalis Pharmaceuticals' net income changed over the last 6 years?

What is Zentalis Pharmaceuticals' operating income?

How has Zentalis Pharmaceuticals' revenue changed over the last 6 years?

How much debt does Zentalis Pharmaceuticals have?

How much cash does Zentalis Pharmaceuticals have?

How has Zentalis Pharmaceuticals' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools